The study compared more than 18,000 patients and found that tirzepatide (Mounjaro) led to a 15% body weight loss as opposed to 8% with semaglutide (Ozempic), yet both had similar side effects and dropout rates.
Over 70% of Americans are classified as overweight and 40% as obese, indicating a societal reliance on injections over addressing the root causes of weight issues.
The pharmaceutical industry's focus on pricey injectable medications like Ozempic and Mounjaro fails to tackle the multifactorial nature of weight gain, leading to unsustainable solutions.
The study revealed a concerning disparity where the majority of participants, especially those prescribed tirzepatide, were middle-class white women, shedding light on potential access inequalities.
Collection
[
|
...
]